GC Biopharma has won its first-ever government contract in Malaysia for plasma-derived products, marking the first time a Korean company has displaced CSL Behring—the global market leader in plasma therapies—in the country’s state-run procurement process.
On June 2, GC Biopharma announced that it had signed a toll-manufacturing agreement with Solid Intellectual SDN BHD (SISB), a subsidiary of Malaysia’s prominent JAKEL Group, for the supply of plasma-derived therapeutics.
JAKEL Group is a leading Malaysian private conglomerate with diverse business interests. SISB handles the group’s pharmaceutical and medical device distribution.
The agreement follows a successful bid in March by GC Biopharma and SISB to participate in Malaysia’s national plasma fractionation program. This marks the first time an Asian company has been selected as the sole contractor for the project.
Under the contract, Malaysia’s health authorities will provide domestically collected plasma to SISB, which will then deliver it to GC Biopharma. The company will manufacture finished plasma-derived products—such as albumin and immunoglobulin—and export them back to SISB for distribution within Malaysia.
GC Biopharma plans to supply plasma-derived medicines worth at least $24 million (approximately KRW 33 billion) over a minimum four-year period beginning in 2026.
The agreement is especially noteworthy as GC Biopharma is replacing CSL Behring, which has held a monopoly on the program in Malaysia for the past 15 years. CSL Behring remains the global leader in the plasma fractionation market.
“We will continue to strengthen our position in the global plasma-derived therapeutics market through strategic partnerships between countries,” said Woojin Lee, Head of Global Business at GC Biopharma.
